Sight Sciences Announces Publication of a New Analysis from The ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved with OMNI® Across Mild, Moderate, and Advanced Glaucoma

Core Insights - Sight Sciences, Inc. announced new findings from the ROMEO study, indicating that the OMNI Surgical System is effective in treating advanced glaucoma patients, challenging previous beliefs about treatment efficacy in severe cases [1][2][3] Group 1: Study Findings - The analysis showed that ab interno canaloplasty combined with trabeculotomy using OMNI effectively lowered intraocular pressure (IOP) and reduced medication usage across all glaucoma severity stages [2][3] - Significant reductions in IOP and IOP-reducing medications were observed, with 70% of eyes experiencing IOP reduction at Month 12, and 92% achieving levels of 18 mmHg or less [7] - The mean IOP at Month 12 ranged between 14 mmHg and 16 mmHg across severity groups, indicating consistent treatment outcomes [7] - Medication reductions were noted in 50% to 69% of patients, with the majority showing a reduction of at least one medication [7] - Regression analysis indicated no significant relationship between Month 12 IOP and visual field loss, suggesting treatment effectiveness is independent of disease severity [7] Group 2: Company Overview - Sight Sciences is focused on developing innovative eyecare technologies aimed at transforming patient care and improving lives, particularly through minimally invasive procedures [1][8] - The OMNI Surgical System is FDA-cleared for reducing IOP in adult patients with primary open-angle glaucoma, and it is CE Marked for additional procedures [8] - The company also offers the TearCare System for treating evaporative dry eye disease and the SION Surgical Instrument for ophthalmic surgeries [8]